

Abdominal Aortic Aneurysm Guideline Committee – development

Date: 29/01/2018 – 30/01/2018

Location: NICE offices, Manchester

Minutes: Final



Committee members present:		
	Day 1	Day 2
Andrew Bradbury (AB) – Chair	Present for all	Present for all
Chris Hammond (CH)	Present from partway through item 2	Present from partway through item 2
Mark Hampshire (MH)	Present for all	Present for all
Karen Jellett (JK)	Present from partway through item 2	Present for all
Jaqui Lindridge (JL)	Present for all	Present for all
Adam Pichel (AP)	Present for all	Present for all
Tamsin Ribbons (TR)	Present for all	Present for all
Les Ruffell (LR)	Present for all	Present for all
Matthew Slater (MS)	Present for all	Present for all
Alan Huw Smith (AS)	Present for all	Present for all
Sammer Tang (ST)	Present for all	Present for all
Hazel Trender (HT)	Present for all	Present for all
Noel Wilson (NW)	Present for all	Present for all

In attendance:		
	Day 1	Day 2
Jamie Elvidge (JE) Senior Analyst – HE	Present for all	Apologies
Gareth Franklin (GF) Medicines Adviser	Present for items 3 and 4	Apologies
James Hall (JH) Senior Medical Editor	Present for all	Present for all
Caroline Mulvihill (CM) Technical Adviser	Present for all	Present for all
Gareth Murphy (GM) Business Analyst	Present for all	Present for all
Adam O’Keefe (AO) Project Manager	Present for all	Present for all
Gabriel Rogers (GR) Technical Adviser (HE)	Present for all	Present for all
Jeffrey Tabiri-Essuman (JT) Technical Analyst	Present for all	Present for all
Shreya Shukla (SSh) Technical Analyst	Present until item 5	Apologies
Sue Spiers (SS) Associate Director	Present for all	Present for all

Observers:		
	Day 1	Day 2
Sophie Cooper Technical Analyst, NICE	Present until partway through item 4 and then from partway through item 5	Present for item 2
Michael Raynor Information Specialist, NICE	Present until partway through item 5	Apologies

Apologies:
Ivan Benett – Committee member
Alun Huw Davies – Committee member
Jugdeep Dhesi – Committee member
Justine Karpusheff – NICE Guidelines Commissioning Manager
Sarah Glover – NICE Information Specialist
Lisa Stone – NICE Medicines Adviser

Day 1 Monday 29 January 2018:

1. Welcome, apologies, minutes of the last meeting, declarations of interest
<p><u>Welcome</u></p> <p>The Chair welcomed the Committee members and attendees to day one of the fifteenth meeting of the abdominal aortic aneurysm guideline committee.</p> <p><u>Apologies</u></p> <p>Apologies for the meeting were received as detailed above.</p> <p><u>Objectives</u></p> <p>The Chair outlined the main objectives of the day, which included evidence reviews for Review Questions 6, 20 and 28 and presentation of the final Health Economic model.</p> <p><u>Minutes of the last meeting</u></p> <p>The minutes were agreed as an accurate record of the previous meeting.</p> <p><u>Declarations of interest</u></p> <p>Each committee member was asked to declare any new conflicts since the previous meeting. No new interests were declared.</p> <p>Having reviewed the historical declaration of interests table, which was provided to the committee, the Chair declared that all committee members present were eligible to attend the meeting and contribute to the discussions and drafting of any recommendations.</p>

2. Review Question 20: Does tranexamic acid improve a person's chance of survival or improve the stability of their condition in the transfer of people with ruptured or symptomatic abdominal aortic aneurysms to a specialist vascular unit?

JT informed the committee that no relevant evidence had been identified for Review Question 20 and provided an explanation for the reasons studies had been excluded. No relevant health economic evidence had been identified.

Committee members acknowledged the lack of evidence but discussed their own current clinical practice in this area. Due to the lack of evidence, the committee felt unable to draft any practice recommendations. The committee agreed that further research in this area would be welcomed so drafted one research recommendation.

3. Review Question 28: When checking people after they have had EVAR or open repair of an abdominal aortic aneurysm, which imaging techniques are most useful for detecting postoperative complications, further aneurysm expansion and aneurysm rupture?

SS recapped the search protocol and presented the clinical evidence supporting Review Question 28 for the committee's consideration.

The committee discussed the evidence presented and drafted three recommendations.

4. Review Question 6: Which non-surgical interventions (including drug treatment and risk factor management) are effective in slowing aneurysm expansion and reducing the risk of rupture?

JT recapped the search protocol and presented the clinical evidence supporting Review Question 6 for the committee's consideration.

The committee discussed the evidence presented but decided not to draft any recommendations.

5. Presentation of final economic model

JE and GR presented to the committee the final version of the health economic model developed to inform the guideline. The committee then revisited and edited recommendations previously drafted on Review Question 23: What is the effectiveness of EVAR compared to open repair surgery in repairing ruptured abdominal aortic aneurysms?

6. Next steps

The Chair thanked the committee for their input and confirmed day 2 would commence at 9am.

Day 2 Tuesday 30 January 2018:

1. Welcome, apologies, declarations of interest

Introduction

The Chair welcomed the Committee members and attendees to day two of the fifteenth meeting of the abdominal aortic aneurysm guideline committee.

Apologies

Apologies for the meeting were received as detailed above.

Objectives

The Chair provided a brief overview and objectives of the day highlighting the information that would be discussed.

Declarations of interest

Each committee member was asked to declare any new conflicts. No new interests were declared.

The Chair confirmed that the committee members present were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

2. Review short guideline; Re-runs

The committee reviewed the structure of the short version of the guideline.

JT and GR presented additional clinical and health economic evidence that had been identified for a number of review questions. The committee discussed this evidence and amended draft recommendations accordingly.

The committee discussed and agreed the research recommendations drafted to date but due to time constraints, it was agreed that the prioritisation of the five research recommendations to be listed in the short version of the guideline as priorities for further research will be agreed via email following the meeting.

3. Next steps

AO provided the committee with details and dates of next steps prior to guideline consultation.

The Chair thanked the committee for their time and contribution to Day 2. The venue, date and time of the next meeting was confirmed:

Date of next meeting: Post-consultation meeting on Wednesday 25 July.

Location of next meeting: NICE offices, Manchester.